Lumenis Announces Support of Successful Health Mission to Provide Medical Treatment to Underserved Population

YOKNEAM, Israel, March 15, 2017 -- Lumenis Ltd., the world’s largest energy-based medical device company for surgical, aesthetic and ophthalmic applications, announced successful outcomes directly tied to their support of Global, Surgical, Destination, Healthcare (GSD) Inc.'s Medical Mission to Haiti. As a result of the mission, the 5th of its kind, over 100 patients were seen and treated during the course of the 6 day visit, which included 50 surgeries.

Advanced Lumenis prostate enucleation technology was used to treat the patients suffering from benign prostatic hyperplasia (BPH). BPH occurs in most men as they age. It has been estimated that 50% to 60% of men in their 60s and 80% to 90% of men in their 70s and 80s have BPH.¹

The humanitarian effort was led by Mitchell Humphreys, MD, a urologist with the Mayo Clinic in Arizona and sponsored by the non-profit organization GSD, with Lumenis technology playing an integral role on-site.

“Men who suffer from BPH experience symptoms such as increased frequency and urgency of urination. Our work from the mission left a huge impact on the people of Haiti – it was incredibly moving to treat these patients suffering from BPH allowing these men to be husbands, fathers, and the freedom to be present within their community,” said Humphreys. “During the mission, we used the Lumenis 100W Laser, which was critical in treating these patients, as the technology allowed us to treat many patients in a short amount of time with favorable outcomes, and ultimately, enhance their quality of life.”

When symptoms advance in severity and are left untreated, they can lead to serious medical conditions. While BPH is an easily treated condition with medication or surgery in developed countries, the condition is commonly left untreated in underdeveloped populations worldwide.

“With a commitment to delivering innovation to improve the health and well-being of patients all over the world, Lumenis is honored to be a part of the fifth Medical Mission to Haiti,” said Tzipi Ozer-Armon, CEO of Lumenis. “We are proud to provide holmium laser technology in support of bringing healthcare and humanitarian assistance to those patients suffering with BPH in Haiti. We would like to extend a special thank you to Dr. Humphreys, who collaborated with us on this meaningful mission. As we look ahead, we look forward to furthering our partnerships with key leaders of the medical community to continue establishing important programs and initiatives to offer life-changing treatments to patients globally.”

The Medical Mission to Haiti’s ongoing focus is to promote men’s health and foster local partnerships to improve healthcare delivery systems for long-term sustainability. Through patient education and compassionate care, the mission strives to restore community values through the patriarchs of families by way of medical intervention that is otherwise unavailable within their local communities.

Lumenis’ 100W Laser, a versatile laser solution for the treatment of BPH and other medical conditions, was donated and used during the mission. Holmium laser technology is a powerful and reliable way to treat men with BPH.

For more information about the Lumenis Holmium Laser Solutions, please visit: http://www.lumenis.com/Solutions/Surgical/Products/Holmium-Product-Family

About Lumenis
www.lumenis.com
Lumenis is the world’s largest energy-based medical device company for surgical, aesthetic and ophthalmic applications in the area of minimally invasive clinical solutions. Regarded as a world-renowned expert in developing and commercializing innovative energy-based technologies, including Laser, Intense Pulsed Light (IPL) and Radio-Frequency (RF). For nearly 50 years, Lumenis' ground-breaking products have redefined medical treatments and have set numerous technological and clinical gold-standards. Lumenis has successfully created solutions for previously untreatable conditions, as well as designed advanced technologies that have revolutionized existing treatment methods.

¹ Roehrborn CG. Benign Prostatic Hyperplasia: An Overview. Rev Urology 2005; 7 (suppl 9): S3-S14.

MEDIA CONTACT
Cassandra Dump, Pascale Communications
[email protected]
619.971.1887